Self-Amplifying Replicon RNA Delivery to Dendritic Cells by Cationic Lipids

Molecular Therapy Nucleic Acids

Volumn 12, Issue , 2018, Pages 118-134

  Englezou, Pavlos C ^a   Sapet, Cedric ^c   Démoulins, Thomas ^a   Milona, Panagiota ^a   Ebensen, Thomas ^b   Schulze, Kai ^b   Guzman, Carlos Alberto ^b   Poulhes, Florent ^c   Zelphati, Olivier ^c   Ruggli, Nicolas ^a   McCullough, Kenneth C ^a  

^a INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (Switzerland)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^c Case 922   (France)

Author keywords

cationic lipids; cellular immunity; dendritic cells; humoral immunity; influenza vaccines; nanoparticle delivery; replicon; RepRNA; self amplifying

Indexed keywords

CATION; LIPID; LIPOPLEX; NANOPARTICLE; REPRNA VACCINE; UNCLASSIFIED DRUG; VACCINE; VIRUS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL SURFACE; CELLULAR IMMUNITY; CLASSICAL SWINE FEVER VIRUS; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DENDRITIC CELL; DISPERSITY; FEMALE; FLOW CYTOMETRY; GENETIC CODE; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA A; INFLUENZA A VIRUS; INTERNALIZATION; MONOCYTE; MOUSE; NONHUMAN; PHOTON CORRELATION SPECTROSCOPY; PIG; PRIORITY JOURNAL; REPLICON; VACCINATION; VIRAL GENE DELIVERY SYSTEM; VIRAL TROPISM; VIRUS LOAD;

EID: 85047643409     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1016/j.omtn.2018.04.019     Document Type: Article

References (62)

1. McCullough, K.C., Bassi, I., Démoulins, T., Thomann-Harwood, L.J., Ruggli, N., Functional RNA delivery targeted to dendritic cells by synthetic nanoparticles. Ther. Deliv. 3 (2012), 1077–1099.
2. Démoulins, T., Milona, P., Englezou, P.C., Ebensen, T., Schulze, K., Suter, R., Pichon, C., Midoux, P., Guzmán, C.A., Ruggli, N., McCullough, K.C., Polyethylenimine-based polyplex delivery of self-replicating RNA vaccines. Nanomedicine (Lond.) 12 (2016), 711–722.
3. McCullough, K.C., Bassi, I., Milona, P., Suter, R., Thomann-Harwood, L., Englezou, P., Démoulins, T., Ruggli, N., Self-replicating Replicon-RNA Delivery to Dendritic Cells by Chitosan-nanoparticles for Translation In Vitro and In Vivo. Mol. Ther. Nucleic Acids, 3, 2014, e173.
4. Tratschin, J.D., Ruggli, N., and McCullough, K.C. (2008). Pestivirus replicons providing an RNA-based viral vector system. US patent application publication 20160108372 A1, filed December 22, 2015, and published April 21, 2016.
5. Brito, L.A., Chan, M., Shaw, C.A., Hekele, A., Carsillo, T., Schaefer, M., Archer, J., Seubert, A., Otten, G.R., Beard, C.W., et al. A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol. Ther. 22 (2014), 2118–2129.
6. Geall, A.J., Verma, A., Otten, G.R., Shaw, C.A., Hekele, A., Banerjee, K., Cu, Y., Beard, C.W., Brito, L.A., Krucker, T., et al. Nonviral delivery of self-amplifying RNA vaccines. Proc. Natl. Acad. Sci. USA 109 (2012), 14604–14609.
7. Brazzoli, M., Magini, D., Bonci, A., Buccato, S., Giovani, C., Kratzer, R., Zurli, V., Mangiavacchi, S., Casini, D., Brito, L.M., et al. Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin. J. Virol. 90 (2015), 332–344.
8. Atkins, G.J., Fleeton, M.N., Sheahan, B.J., Therapeutic and prophylactic applications of alphavirus vectors. Expert Rev. Mol. Med., 10, 2008, e33.
9. Khromykh, A.A., Replicon-based vectors of positive strand RNA viruses. Curr. Opin. Mol. Ther. 2 (2000), 555–569.
10. Pijlman, G.P., Suhrbier, A., Khromykh, A.A., Kunjin virus replicons: an RNA-based, non-cytopathic viral vector system for protein production, vaccine and gene therapy applications. Expert Opin. Biol. Ther. 6 (2006), 135–145.
11. Rayner, J.O., Dryga, S.A., Kamrud, K.I., Alphavirus vectors and vaccination. Rev. Med. Virol. 12 (2002), 279–296.
12. Suter, R., Summerfield, A., Thomann-Harwood, L.J., McCullough, K.C., Tratschin, J.D., Ruggli, N., Immunogenic and replicative properties of classical swine fever virus replicon particles modified to induce IFN-α/β and carry foreign genes. Vaccine 29 (2011), 1491–1503.
13. Ljungberg, K., Liljeström, P., Self-replicating alphavirus RNA vaccines. Expert Rev. Vaccines 14 (2015), 177–194.
14. McCullough, K.C., Milona, P., Démoulins, T., Englezou, P., Ruggli, N., Dendritic Cell Targets for Self-Replicating RNA Vaccines. J. Blood Lymph, 5, 2015, 132.
15. McCullough, K.C., Milona, P., Thomann-Harwood, L., Démoulins, T., Englezou, P., Suter, R., Ruggli, N., Self-amplifying replicon RNA vaccine delivery to dendritic cells by synthetic nanoparticles. Vaccines (Basel) 2 (2014), 735–754.
16. Mellman, I., Steinman, R.M., Dendritic cells: specialized and regulated antigen processing machines. Cell 106 (2001), 255–258.
17. Steinman, R.M., Pope, M., Exploiting dendritic cells to improve vaccine efficacy. J. Clin. Invest. 109 (2002), 1519–1526.
18. Kumari, S., Mg, S., Mayor, S., Endocytosis unplugged: multiple ways to enter the cell. Cell Res. 20 (2010), 256–275.
19. Platta, H.W., Stenmark, H., Endocytosis and signaling. Curr. Opin. Cell Biol. 23 (2011), 393–403.
20. Luo, D., Saltzman, W.M., Synthetic DNA delivery systems. Nat. Biotechnol. 18 (2000), 33–37.
21. Lundstrom, K., Replicon RNA Viral Vectors as Vaccines. Vaccines (Basel), 4, 2016, E39.
22. Andries, O., Kitada, T., Bodner, K., Sanders, N.N., Weiss, R., Synthetic biology devices and circuits for RNA-based 'smart vaccines’: a propositional review. Expert Rev. Vaccines 14 (2015), 313–331.
23. Rodríguez-Gascón, A., del Pozo-Rodríguez, A., Solinís, M.A., Development of nucleic acid vaccines: use of self-amplifying RNA in lipid nanoparticles. Int. J. Nanomedicine 9 (2014), 1833–1843.
24. Zelphati, O., and Moutard, S. (2009). New class of cationic lipids for transporting active agents into cells. US patent application publication US20120015865 A1, filed February 16, 2011, and published January 19, 2012.
25. Zelphati, O., Szoka, F.C. Jr., Mechanism of oligonucleotide release from cationic liposomes. Proc. Natl. Acad. Sci. USA 93 (1996), 11493–11498.
26. Hattori, Y., Hara, E., Shingu, Y., Minamiguchi, D., Nakamura, A., Arai, S., Ohno, H., Kawano, K., Fujii, N., Yonemochi, E., siRNA delivery into tumor cells by cationic cholesterol derivative-based nanoparticles and liposomes. Biol. Pharm. Bull. 38 (2015), 30–38.
27. Auray, G., Keller, I., Python, S., Gerber, M., Bruggmann, R., Ruggli, N., Summerfield, A., Characterization and Transcriptomic Analysis of Porcine Blood Conventional and Plasmacytoid Dendritic Cells Reveals Striking Species-Specific Differences. J. Immunol. 197 (2016), 4791–4806.
28. Link, C., Gavioli, R., Ebensen, T., Canella, A., Reinhard, E., Guzmán, C.A., The Toll-like receptor ligand MALP-2 stimulates dendritic cell maturation and modulates proteasome composition and activity. Eur. J. Immunol. 34 (2004), 899–907.
29. Borsutzky, S., Fiorelli, V., Ebensen, T., Tripiciano, A., Rharbaoui, F., Scoglio, A., Link, C., Nappi, F., Morr, M., Buttó, S., et al. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant. Eur. J. Immunol. 33 (2003), 1548–1556.
30. Rharbaoui, F., Drabner, B., Borsutzky, S., Winckler, U., Morr, M., Ensoli, B., Mühlradt, P.F., Guzmán, C.A., The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant. Eur. J. Immunol. 32 (2002), 2857–2865.
31. García-Sastre, A., Mena, I., Novel vaccine strategies against emerging viruses. Curr. Opin. Virol. 3 (2013), 210–216.
32. Aronsohn, A.I., Hughes, J.A., Nuclear localization signal peptides enhance cationic liposome-mediated gene therapy. J. Drug Target. 5 (1998), 163–169.
33. Brisson, M., Tseng, W.C., Almonte, C., Watkins, S., Huang, L., Subcellular trafficking of the cytoplasmic expression system. Hum. Gene Ther. 10 (1999), 2601–2613.
34. Lundstrom, K., Alphavirus-based vaccines. Curr. Opin. Mol. Ther. 4 (2002), 28–34.
35. Zimmer, G., RNA replicons - a new approach for influenza virus immunoprophylaxis. Viruses 2 (2010), 413–434.
36. Mintzer, M.A., Simanek, E.E., Nonviral vectors for gene delivery. Chem. Rev. 109 (2009), 259–302.
37. Tros de Ilarduya, C., Sun, Y., Düzgüneş, N., Gene delivery by lipoplexes and polyplexes. Eur. J. Pharm. Sci. 40 (2010), 159–170.
38. Belizaire, R., Unanue, E.R., Targeting proteins to distinct subcellular compartments reveals unique requirements for MHC class I and II presentation. Proc. Natl. Acad. Sci. USA 106 (2009), 17463–17468.
39. Granot, Y., Peer, D., Delivering the right message: Challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeutics-An innate immune system standpoint. Semin. Immunol. 34 (2017), 68–77.
40. Riley, M.K., Vermerris, W., Recent Advances in Nanomaterials for Gene Delivery-A Review. Nanomaterials (Basel), 7, 2017, E94.
41. Cullis, P.R., Hope, M.J., Lipid Nanoparticle Systems for Enabling Gene Therapies. Mol. Ther. 25 (2017), 1467–1475.
42. Jiang, L., Vader, P., Schiffelers, R.M., Extracellular vesicles for nucleic acid delivery: progress and prospects for safe RNA-based gene therapy. Gene Ther. 24 (2017), 157–166.
43. Guan, S., Rosenecker, J., Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems. Gene Ther. 24 (2017), 133–143.
44. Hughes, G.A., Nanostructure-mediated drug delivery. Nanomedicine 1 (2005), 22–30.
45. Rao, N.M., Gopal, V., Cell biological and biophysical aspects of lipid-mediated gene delivery. Biosci. Rep. 26 (2006), 301–324.
46. Tresset, G., The multiple faces of self-assembled lipidic systems. PMC Biophys., 2, 2009, 3.
47. Dan, N., Danino, D., Structure and kinetics of lipid-nucleic acid complexes. Adv. Colloid Interface Sci. 205 (2014), 230–239.
48. Caracciolo, G., Pozzi, D., Amenitsch, H., Caminiti, R., Multicomponent cationic lipid-DNA complex formation: role of lipid mixing. Langmuir 21 (2005), 11582–11587.
49. Oberle, V., Bakowsky, U., Zuhorn, I.S., Hoekstra, D., Lipoplex formation under equilibrium conditions reveals a three-step mechanism. Biophys. J. 79 (2000), 1447–1454.
50. Hsu, W.L., Chen, H.L., Liou, W., Lin, H.K., Liu, W.L., Mesomorphic complexes of DNA with the mixtures of a cationic surfactant and a neutral lipid. Langmuir 21 (2005), 9426–9431.
51. Wasungu, L., Hoekstra, D., Cationic lipids, lipoplexes and intracellular delivery of genes. J. Control. Release 116 (2006), 255–264.
52. Schijns, V.E., Tangerås, A., Vaccine adjuvant technology: from theoretical mechanisms to practical approaches. Dev. Biol. (Basel) 121 (2005), 127–134.
53. Nimmerjahn, F., Ravetch, J.V., Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310 (2005), 1510–1512.
54. Kawaguchi, M., Adachi, M., Oda, N., Kokubu, F., Huang, S.K., IL-17 cytokine family. J. Allergy Clin. Immunol. 114 (2004), 1265–1273 quiz 1274.
55. Kawaguchi, M., Kokubu, F., Odaka, M., Watanabe, S., Suzuki, S., Ieki, K., Matsukura, S., Kurokawa, M., Adachi, M., Huang, S.K., Induction of granulocyte-macrophage colony-stimulating factor by a new cytokine, ML-1 (IL-17F), via Raf I-MEK-ERK pathway. J. Allergy Clin. Immunol. 114 (2004), 444–450.
56. Lin, Y., Slight, S.R., Khader, S.A., Th17 cytokines and vaccine-induced immunity. Semin. Immunopathol. 32 (2010), 79–90.
57. Démoulins, T., Englezou, P.C., Milona, P., Ruggli, N., Tirelli, N., Pichon, C., Sapet, C., Ebensen, T., Guzmán, C.A., McCullough, K.C., Self-replicating RNA vaccine delivery to dendritic cells. Methods Mol. Biol. 1499 (2017), 37–75.
58. Ruggli, N., Tratschin, J.D., Mittelholzer, C., Hofmann, M.A., Nucleotide sequence of classical swine fever virus strain Alfort/187 and transcription of infectious RNA from stably cloned full-length cDNA. J. Virol. 70 (1996), 3478–3487.
59. Feng, S.S., Nanoparticles of biodegradable polymers for new-concept chemotherapy. Expert Rev. Med. Devices 1 (2004), 115–125.
60. Petri, B., Bootz, A., Khalansky, A., Hekmatara, T., Müller, R., Uhl, R., Kreuter, J., Gelperina, S., Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants. J. Control. Release 117 (2007), 51–58.
61. Champion, J.A., Katare, Y.K., Mitragotri, S., Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers. J. Control. Release 121 (2007), 3–9.
62. Ebensen, T., Libanova, R., Schulze, K., Yevsa, T., Morr, M., Guzmán, C.A., Bis-(3′,5′)-cyclic dimeric adenosine monophosphate: strong Th1/Th2/Th17 promoting mucosal adjuvant. Vaccine 29 (2011), 5210–5220.